196 related articles for article (PubMed ID: 34115234)
1. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab-associated glomerular microangiopathy.
Person F; Rinschen MM; Brix SR; Wulf S; Noriega MLM; Fehrle W; Schmitz J; Schwarz A; Ivanyi P; Steinmetz OM; Reinhard L; Hoxha E; Zipfel PF; Bräsen JH; Wiech T
Mod Pathol; 2019 May; 32(5):684-700. PubMed ID: 30552416
[TBL] [Abstract][Full Text] [Related]
3. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer.
Morimoto M; Arai T; Matsuura M; Ono Y
CEN Case Rep; 2021 Feb; 10(1):6-11. PubMed ID: 32642991
[TBL] [Abstract][Full Text] [Related]
5. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.
Nagayama Y; Yamano M; Yagame M; Nariyama T; Takahashi M; Kawamoto M; Matsui K
BMC Nephrol; 2019 Oct; 20(1):375. PubMed ID: 31623576
[TBL] [Abstract][Full Text] [Related]
6. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
8. VEGF inhibition and renal thrombotic microangiopathy.
Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
[TBL] [Abstract][Full Text] [Related]
9. Renal thrombotic microangiopathy in mice with combined deletion of endocytic recycling regulators EHD3 and EHD4.
George M; Rainey MA; Naramura M; Foster KW; Holzapfel MS; Willoughby LL; Ying G; Goswami RM; Gurumurthy CB; Band V; Satchell SC; Band H
PLoS One; 2011 Mar; 6(3):e17838. PubMed ID: 21408024
[TBL] [Abstract][Full Text] [Related]
10. VEGF regulates local inhibitory complement proteins in the eye and kidney.
Keir LS; Firth R; Aponik L; Feitelberg D; Sakimoto S; Aguilar E; Welsh GI; Richards A; Usui Y; Satchell SC; Kuzmuk V; Coward RJ; Goult J; Bull KR; Sharma R; Bharti K; Westenskow PD; Michael IP; Saleem MA; Friedlander M
J Clin Invest; 2017 Jan; 127(1):199-214. PubMed ID: 27918307
[TBL] [Abstract][Full Text] [Related]
11. Proteinuria in thrombotic microangiopathy is associated with partial podocytopathy.
Moore M; Afolayan-Oloye O; Kroneman O; Li W; Kanaan HD; Zhang PL
Ultrastruct Pathol; 2023 May; 47(3):219-226. PubMed ID: 36906888
[TBL] [Abstract][Full Text] [Related]
12. Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus.
Veron D; Villegas G; Aggarwal PK; Bertuccio C; Jimenez J; Velazquez H; Reidy K; Abrahamson DR; Moeckel G; Kashgarian M; Tufro A
PLoS One; 2012; 7(7):e40589. PubMed ID: 22808199
[TBL] [Abstract][Full Text] [Related]
13. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
Zhang PL; Raza S; Li W; Kanaan HD
Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease.
Veron D; Reidy KJ; Bertuccio C; Teichman J; Villegas G; Jimenez J; Shen W; Kopp JB; Thomas DB; Tufro A
Kidney Int; 2010 Jun; 77(11):989-99. PubMed ID: 20375978
[TBL] [Abstract][Full Text] [Related]
15. Podocyte Involvement in Renal Thrombotic Microangiopathy: A Clinicopathological Study.
Hu YF; Tan Y; Yu XJ; Wang H; Wang SX; Yu F; Zhao MH
Am J Nephrol; 2020; 51(9):752-760. PubMed ID: 32862175
[TBL] [Abstract][Full Text] [Related]
16. [A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab].
Tomita M; Ochiai M; Shu S; Yamauchi Y; Shihara H; Ogata A; Fujisawa N; Yanai Y; Kamata T; Iehara N
Nihon Jinzo Gakkai Shi; 2014; 56(5):612-7. PubMed ID: 25130034
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-induced thrombotic microangiopathy and nephrotic syndrome.
Shimamura Y; Maeda T; Takizawa H
Clin Exp Nephrol; 2019 Jan; 23(1):142-143. PubMed ID: 29882112
[No Abstract] [Full Text] [Related]
18. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease.
Hakroush S; Moeller MJ; Theilig F; Kaissling B; Sijmonsma TP; Jugold M; Akeson AL; Traykova-Brauch M; Hosser H; Hähnel B; Gröne HJ; Koesters R; Kriz W
Am J Pathol; 2009 Nov; 175(5):1883-95. PubMed ID: 19834063
[TBL] [Abstract][Full Text] [Related]
19. Platelets and capillary injury in acute humoral rejection of renal allografts.
Meehan SM; Limsrichamrern S; Manaligod JR; Junsanto T; Josephson MA; Thistlethwaite JR; Haas M
Hum Pathol; 2003 Jun; 34(6):533-40. PubMed ID: 12827606
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: A case series and systematic review of the literature.
Hilburg R; Geara AS; Qiu MK; Palmer MB; Chiang EY; Burger RA; Hogan JJ
Clin Nephrol; 2021 Jul; 96(1):51-59. PubMed ID: 33896447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
